Claims for Patent: 10,093,689

Summary for Patent: 10,093,689

Title:	Composition containing a gold (I) complex and cancer cells
Abstract:	Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
Inventor(s):	Al-Jaroudi; Said S. (Dhahran, SA), Alhoshani; Ali (Riyadh, SA), Altaf; Muhammad (Dhahran, SA), Isab; Anvarhusein Abdulkadir (Dhahran, SA)
Assignee:	King Fahd University of Petroleum and Minerals (Dhahran, SA) King Saud University (Riyadh, SA)
Application Number:	15/990,289
Patent Claims:	1. A composition, comprising: a gold(I) complex represented by formula (I): ##STR00006## a salt thereof, a solvate thereof, or a combination thereof; cancer cells; and at least one chemotherapeutic agent selected from the group consisting of aflibercept, asparaginase, bleomycin, busulfan, carmustine, chlorambucil, cladribine, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, doxorubicin, etoposide, fludarabine, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin, mitoxantrone, pentostatin, procarbazine, topotecan, vinblastine, vincristine, retinoic acid, oxaliplatin, carboplatin, 5-fluorouracil, teniposide, amasacrine, docetaxel, paclitaxel, vinorelbine, bortezomib, clofarabine, capecitabine, actinomycin D, epirubicin, vindesine, methotrexate, 6-thioguanine, tipifarnib, imatinib, erlotinib, sorafenib, sunitinib, dasatinib, nilotinib, lapatinib, gefitinib, temsirolimus, everolimus, rapamycin, bosutinib, pzopanib, axitinib, neratinib, vatalanib, pazopanib, midostaurin, enzastaurin, trastuzumab, cetuximab, panitumumab, rituximab, bevacizumab, mapatumumab, conatumumab, and lexatumumab; wherein R.sub.1 and R.sub.2 are alkyl groups independently selected from the group consisting of methyl, ethyl and isopropyl; R.sub.3, R.sub.4, and R.sub.5 are independently selected from the group consisting of an optionally substituted C.sub.1-C.sub.3 alkyl, an optionally substituted C.sub.3-C.sub.5 cycloalkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted arylolefin, an optionally substituted vinyl; and with the proviso that R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are not each an ethyl. 2. The gold(I) complex of claim 1, wherein R.sub.1 and R.sub.2 are the same, and R.sub.3, R.sub.4, and R.sub.5 are the same optionally substituted C.sub.1-C.sub.3 alkyl group. 3. The gold(I) complex of claim 2, wherein R.sub.1 and R.sub.2 are methyls, and R.sub.3, R.sub.4, and R.sub.5 are selected from the group consisting of methyl, ethyl, and isopropyl. 4. The gold(I) complex of claim 2, wherein R.sub.1 and R.sub.2 are ethyls, and R.sub.3, R.sub.4, and R.sub.5 are methyls. 5. The gold(I) complex of claim 1, wherein R.sub.1 and R.sub.2 are methyls and R.sub.3, R.sub.4, and R.sub.5 are ethyls. 6. The gold(I) complex of claim 1, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are each a methyl group.

Details for Patent 10,093,689

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978	10,093,689	2036-04-22
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,093,689	2036-04-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	10,093,689	2036-04-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	10,093,689	2036-04-22
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	February 12, 2004	10,093,689	2036-04-22
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	March 28, 2007	10,093,689	2036-04-22
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004	10,093,689	2036-04-22